Critical Warnings & Restrictions In Canada

Basic Chloroquine Information

• INN (International Nonproprietary Name): Chloroquine
• Brand Names Available In Canada (English): not specified
• ATC Code: P01BA01
• Forms & Dosages: Tablets 100 mg, 150 mg, 250 mg, 500 mg; Syrup/Solution 50 mg/5 ml (pediatric); Injectable forms 150 mg base/ml (limited use)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries

Health Canada and provincial regulators consider cardiac and ophthalmic safety central when dispensing chloroquine.

Chloroquine is treated as a high‑risk prescription medicine in most jurisdictions, so pharmacists must verify product registration and a DIN before dispensing or reimbursing.

Screening priorities at point of care include cardiac disease, existing visual or retinal changes, a history of epilepsy, severe liver or kidney impairment, and concurrent use of QT‑prolonging drugs.

Use this quick checklist before supply.

• Checklist: current ECG/QTc status, ophthalmology history, seizure history, liver and renal function tests, full medication list including OTC and naturopathic products.

Monitoring & Reporting

Recommend a baseline ECG with QTc measurement before starting therapy for adults at risk.

For patients on prolonged therapy, arrange baseline ophthalmologic exam and scheduled follow‑up exams per the product monograph.

Check baseline liver and renal laboratories and repeat according to comorbidity and specialist advice.

Medication reconciliation must include over‑the‑counter products, herbal remedies and naturopathic agents that may lower seizure threshold or interact via QT prolongation.

Report suspected adverse reactions to Health Canada through the Canada Vigilance program.

High-Risk Groups (Elderly, Pregnant, Indigenous Health Considerations)

Elderly patients are at increased risk of cardiotoxicity and drug accumulation with chloroquine.

• Monitoring For Elderly: ECG (baseline and periodic), renal function, liver enzymes, review of all medications, visual assessment referral.
• Dose Adjustment: consider lower dose or extended intervals and close follow‑up.

Pregnancy and breastfeeding data are limited, so chloroquine should be used only if expected benefits outweigh risks and under specialist advice.

Perinatal counselling should cover potential maternal adverse effects, neonatal monitoring needs and lactation guidance.

Indigenous health considerations require culturally safe care, collaboration with Indigenous health liaisons or community health nurses and attention to access barriers such as geography and formulary coverage.

Paediatric dosing must be weight‑based; a standard acute malaria paediatric schedule is 10 mg/kg base initially then 5 mg/kg at 6, 24 and 48 hours.

Workers whose roles depend on clear vision or balance should inform occupational health if treatment causes dizziness or visual changes.

Interaction With Activities

Chloroquine can cause dizziness, blurred vision, mood changes and, rarely, seizures.

Advise patients not to drive or operate heavy machinery until they are certain the medicine does not impair them.

Include activity warnings in dispensing counselling and on patient information leaflets.

For safety‑sensitive occupations, workers should notify their employer medical officer and follow provincial occupational health guidance.

Q&A — “Can I Drive After Taking It In Canada?”

Q: Can I drive after a dose of chloroquine?

A: There is no blanket rule; patients should avoid driving if they experience dizziness, significant visual disturbance or drowsiness.

Document counselling in the patient record and advise commercial drivers to follow provincial medical fitness‑to‑drive regulations and employer policies.

Usage Basics For Canadians

INN, Brand Names Available In Canada

INN: chloroquine.

• Common international brands include Aralen, Nivaquine, Lariago and Emquin, but Canadian brand availability is not specified in the public data.
• Pharmacist Action Steps: check the Health Canada Drug Product Database for a DIN and product monograph before supply.
• Pharmacist Action Steps: confirm formulation and strength against the prescription.
• Pharmacist Action Steps: verify manufacturer and GMP certification when sourcing stock.

Legal Classification Under Health Canada

Treat chloroquine as prescription‑only and verify a valid prescription prior to dispensing.

Check the DIN on the product and ensure labelling meets provincial requirements, including bilingual labelling where required.

When a prescriber indicates an off‑label use, confirm prescriber authority, document informed consent and note the clinical rationale in the patient file.

Canadian Dosing Guide

Standard Regimens (Health Canada Approved)

Use the following standard dosing references as a pharmacy quick guide; always cross‑check with the product monograph and specialist advice.

Adjustments For Comorbidities

Diabetes is not an absolute contraindication, but antimalarials have been associated with hypoglycaemia; monitor blood glucose when clinically indicated.

In renal or severe hepatic impairment, and in elderly patients, reduce dose or extend dosing intervals to lower accumulation risk.

If monitoring is required by the product monograph or specialist, arrange ECG, liver and renal testing at baseline and periodically.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

Q: Missed dose — what should I do?

A: Take the missed dose as soon as remembered unless it is almost time for your next scheduled dose; do not double dose.

For provincial drug plan refills, contact your pharmacy for an emergency supply or to facilitate physician renewal.

Interaction Chart (Canadian Context)

Food And Drinks

Alcohol can worsen liver injury and increase dizziness risk; advise moderation and extra caution for patients with alcohol use disorder.

• Counselling Point: suggest taking doses with food to reduce gastrointestinal upset.
• Counselling Point: avoid excessive alcohol while on treatment.

Common Drug Conflicts

High‑risk interactions include other QT‑prolonging agents, drugs that lower seizure threshold and medicines that alter hepatic metabolism.

User Reports & Trends In Canada

Canadian Patient Forums And Review Platforms

Online discussion themes include concerns about visual and cardiac side effects and difficulties sourcing product when requested.

There was a notable spike in public interest during the COVID‑19 period, but authoritative bodies have since limited off‑label use.

Verify anecdotal reports against clinical sources before advising patients.

Community Pharmacy Feedback

Pharmacists report infrequent dispensing requests and frequent need to liaise with specialists for rheumatology indications.

Front‑line queries often relate to off‑label COVID‑related use; current guidance discourages such use outside trials.

• Top Patient Concerns: vision changes, heart symptoms, where to get the medicine, whether it is safe in pregnancy, what monitoring is needed.
• Pharmacist Responses: screen for contraindications, arrange baseline ECG/ophthalmology, report ADRs to Canada Vigilance, refer to specialists.

Access & Purchase Options

National Pharmacy Chains

Chloroquine distribution in Canada can be limited and pharmacies may need to order stock or obtain product through hospital pharmacies.

Call ahead to national chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu to confirm availability.

Pharmacy staff steps: verify DIN, check supplier lead times and confirm authentic manufacturer source before ordering.

Online Pharmacies In Canada & Provincial Restrictions

Online dispensing is allowed if the pharmacy is provincially licensed and follows local dispensing rules and labelling requirements.

For out‑of‑country purchases, Health Canada generally advises against unregulated imports; consult the Personal Importation Policy before ordering abroad.

In our online pharmacy, chloroquine is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

• Patient Checklist: valid prescription (if required), verify DIN and formulation, confirm price and provincial coverage, confirm delivery options.

Mechanism & Pharmacology

Simplified Explanation

Mechanism: chloroquine interferes with parasite lysosomal pH and haem polymerization in Plasmodium species, reducing parasite survival.

Plain Language: the drug traps parasite waste products inside the parasite, which helps kill it.

Absorption

Good oral absorption.

Distribution

Large volume of distribution and long half‑life, leading to tissue accumulation.

Elimination

Hepatic metabolism and renal excretion; impairment raises accumulation risk.

Clinical Terms

Long half‑life explains why cumulative dose matters and why long‑term users require ophthalmologic monitoring for retinopathy.

Pharmacokinetic features support dose adjustments in hepatic or renal impairment and caution in elderly patients.

Indications & Off-Label Uses In Canada

Approved Indications

Primary historic indications include acute malaria and certain rheumatologic conditions and amebiasis; check the product monograph and Health Canada listings for current approved uses and DINs.

Common Off‑Label Practices

Off‑label use should be uncommon, documented and supported by specialist input.

Key Clinical Findings

Canadian And International Studies 2022–2025

Major international trials did not show meaningful benefit for COVID‑19 treatment and regulatory agencies narrowed emergency use authorizations accordingly.

Chloroquine remains effective for chloroquine‑sensitive malaria strains but has been replaced by artemisinin‑based combinations in many regions with resistance.

When advising travellers, consider local resistance patterns and current first‑line therapies.

Ongoing Health Canada Safety Monitoring

Canada maintains pharmacovigilance through Canada Vigilance and provincial ADR networks that monitor signals such as QT prolongation and retinopathy.

Regulatory updates are driven by accumulating safety data and international agency guidance.

Alternatives Matrix

Comparable Medicines With DIN In Canada

Pros And Cons Checklist

• Pros: known antimalarial activity, inexpensive generics available internationally.
• Cons: resistance in many regions, cardiac and retinal toxicity risks, multiple monitoring requirements.
• Switch Checklist: allergies, pregnancy status, comorbidities, interacting drugs, provincial formulary and specialist input.

Common Questions From Canadian Patients

• Is It Safe In Pregnancy? — Use only if benefits outweigh risks and under specialist advice with perinatal counselling.
• Can I Breastfeed? — Limited data; discuss with prescriber and monitor infant if used.
• Will It Affect My Driving? — Avoid driving if you feel dizzy, drowsy or have visual changes.
• What Are The Serious Side Effects? — Seek urgent care for chest pain, fainting, severe vision changes or seizures.
• What If I Overdose? — Overdose can be life‑threatening; go to the nearest emergency department immediately.
• How To Dispose? — Return unwanted medicine via provincial medication return programs; do not flush or throw in household trash.
• How To Get Reimbursement? — Check provincial drug plans (e.g., Ontario Drug Benefit, BC PharmaCare, RAMQ) for special authority or prior authorization requirements.

Coverage & Purchase Comparison Table

Step‑By‑Step Purchase Checklist: obtain a valid prescription (if required), confirm DIN and brand, call your pharmacy for stock and price, check provincial coverage, arrange pickup or insured delivery, and schedule monitoring appointments.

Registration & Regulation

Health Canada Approval

Verify current product registration in the Health Canada Drug Product Database for DIN, product monograph and approved indications before dispensing.

Registration and indication status vary globally and some regulators narrowed indications following COVID‑19 evidence.

DIN Number And Labelling Requirements

A valid DIN is required for marketed products in Canada; pharmacists must validate authenticity, expiry and storage conditions on receipt.

Ensure bilingual labelling where applicable and follow controlled distribution practices for high‑risk medicines.

Supplier verification and GMP provenance are essential when procuring hard‑to‑find stock, and hospital procurement channels may be used when retail supply is unavailable.

Storage & Handling

Standard Canadian Household Conditions

Store chloroquine at room temperature, ideally between 15–25°C, protected from light and moisture.

Keep medicine out of reach of children and emphasise that accidental ingestion, especially by children, can be fatal.

Cold‑Chain Requirements

Most oral preparations do not require cold chain, but injectable or specialty formulations may have manufacturer‑specific storage requirements; check the product monograph.

Pharmacy Handling Checklist: maintain temperature logs, store separately from OTC stock, and secure high‑risk medicines to prevent diversion.

Disposal: instruct patients to use provincial medication return programs rather than household trash or flushing.

Guidelines For Proper Use

Canadian Pharmacist Guidance

Confirm indication and duration, verify cardiac and ophthalmologic history, screen for interacting medicines, and counsel on missed doses and overdose risk.

Document counselling and ensure baseline ECG and ophthalmology referrals for chronic therapy.

Provincial Health Authority Recommendations

Align practice with provincial infectious disease and rheumatology guidance and consult local public health for malaria prophylaxis and post‑travel advice.

For special access or coverage assistance, liaise with provincial drug benefit programs such as Ontario Drug Benefit, BC PharmaCare and RAMQ.

Patient Checklist: take the exact dose prescribed, avoid alcohol, never double dose, seek urgent care for chest pain, fainting, severe vision changes or seizures, and report adverse reactions to Health Canada.

Delivery Across Canada (English)